Bruker vs Idexx Laboratories
Add, change or remove companies; up to four.
The short version
- Idexx Laboratories is the larger business, with $4.3B of revenue in fiscal 2025 against $3.4B for Bruker.
- Idexx Laboratories grew revenue faster (10.4%, against 2.1%).
- Idexx Laboratories kept more of each dollar of sales as operating profit (31.6% operating margin, against 2.0%).
- Idexx Laboratories turned more of its sales into free cash flow (24.6% FCF margin, against 1.3%).
- Idexx Laboratories earned a higher return on the capital invested in it (57.3%, against 0.9%).
| Latest fiscal year | BRKR · FY25 | IDXX · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.8B | $44.4B |
| Revenue | $3.4B | $4.3B |
| Free cash flow | $43.3M | $1.1B |
| Net income | −$8.6M | $1.1B |
| Growth | ||
| Revenue growth | 2.1% | 10.4% |
| 5-year growth | 11.6% | 9.7% |
| Share count change | 1.5% | −2.7% |
| Profitability | ||
| Gross margin | 45.9% | 61.8% |
| Operating margin | 2.0% | 31.6% |
| Net margin | −0.3% | 24.6% |
| FCF margin | 1.3% | 24.6% |
| Return on capital | 0.9% | 57.3% |
| Return on equity | −0.4% | 66.2% |
| Balance sheet | ||
| Net debt | $1.6B | $270M |
| Net debt / EBITDA | 5.5x | 0.2x |
| Dividends and buybacks | $32.8M | $1.2B |
| Valuation & quality | ||
| P/E | — | 39.4x |
| Piotroski F-score | 4 | 8 |
Revenue
FY16
BRKR $1.6B
IDXX $1.8B
FY17
BRKR $1.8B
IDXX $2.0B
FY18
BRKR $1.9B
IDXX $2.2B
FY19
BRKR $2.1B
IDXX $2.4B
FY20
BRKR $2.0B
IDXX $2.7B
FY21
BRKR $2.4B
IDXX $3.2B
FY22
BRKR $2.5B
IDXX $3.4B
FY23
BRKR $3.0B
IDXX $3.7B
FY24
BRKR $3.4B
IDXX $3.9B
FY25
BRKR $3.4B
IDXX $4.3B
BRKR
IDXX
Operating margin
FY16
BRKR 11.3%
IDXX 19.7%
FY17
BRKR 12.4%
IDXX 21.0%
FY18
BRKR 13.8%
IDXX 22.2%
FY19
BRKR 14.5%
IDXX 23.0%
FY20
BRKR 12.5%
IDXX 25.7%
FY21
BRKR 17.1%
IDXX 29.0%
FY22
BRKR 17.1%
IDXX 26.7%
FY23
BRKR 14.7%
IDXX 30.0%
FY24
BRKR 7.5%
IDXX 29.0%
FY25
BRKR 2.0%
IDXX 31.6%
BRKR
IDXX
Free cash flow
FY16
BRKR $93.7M
IDXX $274M
FY17
BRKR $111M
IDXX $299M
FY18
BRKR $191M
IDXX $284M
FY19
BRKR $140M
IDXX $304M
FY20
BRKR $235M
IDXX $541M
FY21
BRKR $190M
IDXX $636M
FY22
BRKR $145M
IDXX $394M
FY23
BRKR $243M
IDXX $773M
FY24
BRKR $136M
IDXX $808M
FY25
BRKR $43.3M
IDXX $1.1B
BRKR
IDXX
Return on capital
FY16
BRKR 21.2%
IDXX —
FY17
BRKR 14.9%
IDXX —
FY18
BRKR 23.8%
IDXX 147.3%
FY19
BRKR 21.6%
IDXX 72.1%
FY20
BRKR 16.6%
IDXX 62.8%
FY21
BRKR 25.1%
IDXX 60.2%
FY22
BRKR 21.0%
IDXX 53.3%
FY23
BRKR 17.5%
IDXX 58.4%
FY24
BRKR 4.8%
IDXX 49.4%
FY25
BRKR 0.9%
IDXX 57.3%
BRKR
IDXX
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.